Stock CGIX CANCER GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Cancer Genetics, Inc.

Equities

CGIX

US13739U2033

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Cancer Genetics, Inc.

Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Cancer Genetics, Inc. has Changed its Ticker to VYNT from CGIX CI
Cancer Genetics, Inc. has Changed its Name to Vyant Bio, Inc CI
Cancer Genetics, Inc.(NasdaqCM:CGIX) dropped from NASDAQ Composite Index CI
StemoniX Inc. completed the acquisition of Cancer Genetics, Inc. from a group of shareholders in a reverse merger transaction. CI
Cancer Genetics : Secures Shareholder Nod for Proposed StemoniX Merger MT
Cancer Genetics, Inc. Appoints Roland J. Carrillo as the Vice President of Business Development CI
Cancer Genetics : to Raise $17.5 Million in Common Stock Offering MT
Cancer Genetics, Inc. announced that it has received $10.000012 million in funding CI
Cancer Genetics, Inc. announced that it expects to receive $10.000012 million in funding CI
Certain Common Stock of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021. CI
Certain Stock Option of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021. CI
Certain Warrants of Cancer Genetics, Inc. are subject to a Lock-Up Agreement Ending on 27-JAN-2021. CI
Cancer Genetics, Inc. Announces Executive Changes CI
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M MT
Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M MT
Cancer Genetics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Cancer Genetics, Inc. Announces Departure of Glenn Miles as Chief Financial Officer, Effective November 16, 2020 CI
Cancer Genetics, Inc. Announces Resignation of Dr. Raju S.K. Chaganti CI
Cancer Genetics, Inc. and StemoniX Inc. Announce Joint Proof of Concept Program CI
StemoniX Inc. entered into a definitive merger agreement to acquire Cancer Genetics, Inc. from a group of shareholders for $55.1 million in a reverse merger transaction. CI
Cancer Genetics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
Cancer Genetics Mulls Strategic Options CI

Chart Cancer Genetics, Inc.

Chart Cancer Genetics, Inc.
More charts

Company Profile

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. CGIX Stock
  4. News Cancer Genetics, Inc.
  5. Cancer Genetics : Earnings Flash (CGIX) CANCER GENETICS Reports Q3 Revenue $1.57M